Allogenic Blood Transfusion During Elective Open Abdominal Aortic Surgery

March 27, 2019 updated by: Katarina Tomulic Brusich, Clinic for Cardiovascular Diseases Magdalena

Allogenic Blood Transfusion During Elective Open Abdominal Aortic Surgery and Its Predictors: a Retrospective Database Study at a Tertiary Hospital in Croatia

Open surgery on the abdominal aorta is a high risk procedure associated with an intravascular volume blood loss and thereby, with high requirement for blood and blood product transfusion.

The aim of this study was to establish the rate for allogenic blood transfusion (ABT) during elective open abdominal aortic surgery and find parameters associated with ABT requirements.

Study Overview

Status

Completed

Conditions

Detailed Description

Two distinct clinical entities affect the abdominal aorta: abdominal aortic aneurysm (AAA) and aortoiliac occlusive disease (AIOD). These are multifactorial vascular disorders caused by complex genetic and environmental factors. Older patients with more comorbidity are often affected. Open abdominal aortic surgery is associated with high mortality rate. Even in specialised institutions it varies from 2 to 5%. Similar results can be compared to mortality for coronary artery bypass grafting. This reflects the complexity of the surgery and the general health of those patients. It is associated with intravascular volume blood loss and, thereby, with a high requirement for blood and blood products transfusion. Allogenic blood transfusion (ABT) has been associated with an increased risk of tumour recurrence, postoperative infection, acute lung injury, perioperative myocardial infarction, postoperative low-output cardiac failure, and increased mortality.

In the last decades, multiple strategies have been undertaken to prevent massive intraoperative blood loss during elective surgery and allogenic blood transfusion requirement. One of the method advocates a preoperative increase in red blood cells level using B12, folic acid and iron supplements or with erythropoietin usage. Other methods involve the optimisation of surgical technique and the use of a machine for intraoperative blood salvage, known as "cell saver".

The aim of this study was to establish the rate for ABT during elective open abdominal aortic surgery, find parameters associated with ABT requirements, and optimise the investigators hospital's maximum surgical blood ordering schedule (MSBOS).

Study Type

Observational

Enrollment (Actual)

426

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

A retrospective cross-sectional study was conducted using an existing computerised medical records database at the Department of Anaesthesiology and Intensive Care at the Clinic for Cardiovascular Diseases Magdalena. This Clinic is a tertiary hospital in Croatia specialised in cardiac and vascular surgery. This study is a retrospective analysis of consecutive patients undergoing elective major vascular surgery who had been prospectively risk-stratified.

Description

Inclusion Criteria:

  • Patients older than 18 years
  • Elective open abdominal aortic surgery
  • Abdominal aortic aneurysm repair
  • Abdominal aortic bypass grafting for occlusive aortoiliac disease

Exclusion Criteria:

  • Patients younger than 18 years
  • Patients undergoing cardiac surgery
  • Patients with ruptured abdominal aneurysms
  • Patients undergoing endovascular aortic repair
  • Patients submitted to other types of vascular surgery (i.e., carotid endarterectomy or peripheral bypass surgery)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Transfused group (TR)
Group received allogenic blood transfusion (ABT) alongside with autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
During elective open aortic surgery, the autologous blood from ICS was processed and re-transfused in all patients. However, TR group additionally received ABT.
Non-transfused (non-TR)
Group received only autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall ABT requirement
Time Frame: Retrospective analysis, 6-year period
Overall ABT requirement (in %) during elective abdominal aortic surgery with the use of ICS for intraoperative blood salvage and autologous transfusion.
Retrospective analysis, 6-year period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Age as the predictor of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
(years)
Retrospective analysis, 6-year period
Gender as the predictors of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
male/female
Retrospective analysis, 6-year period
Body mass index (BMI) as the predictors of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
BMI (kg/m2)
Retrospective analysis, 6-year period
Body surface area (BSA) as the predictors of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
BSA (m²)
Retrospective analysis, 6-year period
Total blood volume as the possible predictors of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
TBV (in liters) calculated trough Nadler's formula
Retrospective analysis, 6-year period
Hemoglobin (Hb) and hematocrit (Htc) as the predictors of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
Hb (g/L) and Htc (%)
Retrospective analysis, 6-year period
Type of illness as the predictor of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
abdominal aortic aneurysm or aortoiliac occlusive disease
Retrospective analysis, 6-year period
Patient's comorbidities as the predictors of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
arterial hypertension, coronary artery disease, diabetes, atrial fibrillation, cerebrovascular incidents, chronic obstructive pulmonary disease, chronic renal insufficiency, malignancy
Retrospective analysis, 6-year period
Medications that impair coagulation and homeostasis as the predictor of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
acetylsalicylic acid, clopidogrel, or warfarin
Retrospective analysis, 6-year period
Postoperative duration of mechanical ventilation
Time Frame: Retrospective analysis, 6-year period
(hours)
Retrospective analysis, 6-year period
Length of stay (LOS)
Time Frame: Retrospective analysis, 6-year period
LOS in ICU (days) and overall hospital LOS (days)
Retrospective analysis, 6-year period
In-hospital mortality rate
Time Frame: Retrospective analysis, 6-year period
(in %)
Retrospective analysis, 6-year period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2011

Primary Completion (ACTUAL)

December 31, 2016

Study Completion (ACTUAL)

October 15, 2018

Study Registration Dates

First Submitted

March 20, 2019

First Submitted That Met QC Criteria

March 23, 2019

First Posted (ACTUAL)

March 27, 2019

Study Record Updates

Last Update Posted (ACTUAL)

March 29, 2019

Last Update Submitted That Met QC Criteria

March 27, 2019

Last Verified

March 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Blood Transfusion

Clinical Trials on Allogenic blood transfusion (ABT)

3
Subscribe